Otsuka announced that the FDA has granted approval of SIMTRIYO (centanafadine), a once-daily extended-release capsule for the treatment of attention-deficit hyperactivity disorder in adults and pediatric patients aged… read more.
Severe workplace violence in forensic psychiatric inpatient care is concentrated in specific everyday situations, ward areas and at certain times of day, according to a study published in… read more.
People with dementia, mild cognitive impairment, alcohol addiction, or psychiatric disorders such as schizophrenia show increased brain ageing, each in specific patterns within the brain, according to a… read more.
Walk into any gym supplement aisle and creatine is there, sold by the tub to people chasing bigger muscles. It is one of the most studied compounds in… read more.
Eisai Co., Ltd. announced that the United Kingdom’s (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has accepted for evaluation a marketing authorization application (MAA) for its in-house-discovered… read more.
Mass General Brigham study suggests that functional brain imaging can help guide accelerated transcranial magnetic stimulation for depression. A new randomized clinical trial from investigators at Mass General… read more.
A self-directed approach to cognitive behavioral therapy for chronic pain (CBT-CP) produces comparable — and in some respects better — outcomes than clinician-delivered CBT-CP, according to a new… read more.
Cognitive behavioural therapies for insomnia (CBT-I) are increasingly being delivered online in order to improve accessibility. However, although insomnia and anxiety frequently occur together in older adults, few… read more.
Researchers have identified the best dosage for each ADHD medication using data from thousands of people with the condition. A new study published today [14 May] in The Lancet… read more.
Current evidence does not support a causal link between the use of almost all antidepressants during pregnancy and an increased risk of neurodevelopmental disorders, including autism and attention-deficit/hyperactivity… read more.
Insomnia is a common problem, affecting as many as 20% to 60% of perimenopausal and postmenopausal US women. Because of its possible severe physical and psychological effects, ongoing… read more.
Johnson & Johnson announced that the FDA has approved a supplemental New Drug Application (sNDA) based on long-term data evaluating the safety and efficacy of Caplyta (lumateperone) for… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
